Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Forschung & Lehre

Duchenne Muskeldystrophie

  • BN 43881 Envol   EudraCT 2022-000691-19
    A TWO-PART, OPEN-LABEL SYSTEMIC GENE DELIVERY STUDY TO EVALUATE THE SAFETY AND EXPRESSION OF RO7494222 (SRP-9001) IN SUBJECTS UNDER THE AGE OF FOUR WITH DUCHENNE MUSCULAR DYSTROPHY
  • PFIZER C3391003 Eudra CT 2019-002921-31
    A phase 3, multicenter, randomized,   double-blind, placebo-controlled study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne Muscular Dystrophy
  • EMBARK SRP-9001-301 Eudra CT 2019-003374-91
    A Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy Who Are Aged 4-7 Years
  • MISSION SRP 4658-402 EudraCT 2018-001762-42
    A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
  • MOMENTUM SRP 5051-201 EudraCT: 2019-000601-77
    A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
  • DSC/142357/51 EUDRACT: 2017-000397-10
    Open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD patients who have been previously treated in one of the GIVINOSTAT studies.
  • PTC PASS
    Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care (Anwendungsbeobachtungsstudie PTC124-GD-025o-DMD)

Spinale Muskelatrophie

  • Biogen 277HV101
    A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previously Treated with Onasemnogene Abeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115
  • ONYX- SRK-015-004
    Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab
  • Sapphire - SRK-015-003 EudraCT Number: 2021-005314-34
    Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
  • Biogen 232SM303 ASCEND EudraCT NUMBER: 2021-001294-23
    A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam
  • BHV-200-301 RESILIENT EudraCT 2022-000193-25

    A Randomized, Double-Blind, PlaceboControlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension

Gliedergürtelmuskeldystrophie

  • SRP-LGMD-501-NH
    Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects with Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), and Type 2C (LGMD2C/R5)

Myasthenia gravis

  • ARGX-113-2006 EudraCT: 2020-005841-18
    Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

 

In Vorbereitung

DMD

  • SRP 9001-303 Envision EudraCT 2020-002372-13
    A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy

  • SRP 9001-305 Expedition
    A Phase 3, Multinational, Long-Term Follow-Up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study

  • PGN-EDO51-103
    Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDO51 with a Long-Term Extension in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (CONNECT2-EDO51)

SMA

  • Roche BN44619 Pupfish
    A PHASE II, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF RISDIPLAM IN INFANTS WITH SPINAL MUSCULAR ATROPHY

LGMD

  • SRP9003-301 Emergene
    LGMD A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4

Myasthenia gravis

  • ARGX-113-2207
    An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

Univ.-Prof. Ulrike Schara-Schmidt

Univ.-Prof. Ulrike Schara-Schmidt

Ltd. Ärztin Kinderneurologie, Stellvertretende Direktorin Klinik für Kinderheilkunde I

0201-723-2508 E-Mail schreiben
Dr. med. Andrea Gangfuß

Dr. med. Andrea Gangfuß

Oberärztin, Fachärztin für Kinderheilkunde mit Schwerpunkt Neuropädiatrie

E-Mail schreiben
fa-female
Ansprechpartnerin

Dr. med. Isabelle Seelmann

Fachärztin für Kinderheilkunde

E-Mail schreiben
 Corinna Seifert
Ansprechpartner

Corinna Seifert

Studienkoordinatorin und Kinderkrankenschwester

E-Mail schreiben
 Karin Smuda
Ansprechpartner

Karin Smuda

Studienkoordinatorin und Kinderkrankenschwester

E-Mail schreiben
 Barbara Andres
Ansprechpartner

Barbara Andres

Physiotherapeutin, Klinische Studien

E-Mail schreiben